Indian (NIFTY) Pharma Industry Analysis

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 09 Aug 2026	₹24.3t	₹4.6t	₹655.4b	29.7x	37.1x	5.3x
Tue, 07 Jul 2026	₹23.8t	₹4.5t	₹643.1b	30.7x	37x	5.3x
Thu, 04 Jun 2026	₹22.0t	₹4.5t	₹643.0b	28.6x	34.2x	4.9x
Sat, 02 May 2026	₹21.0t	₹4.4t	₹619.9b	29x	33.9x	4.8x
Mon, 30 Mar 2026	₹20.1t	₹4.3t	₹621.3b	25.1x	32.4x	4.6x
Wed, 25 Feb 2026	₹20.2t	₹4.3t	₹620.8b	26.6x	32.6x	4.7x
Fri, 23 Jan 2026	₹19.7t	₹4.2t	₹611.6b	27.3x	32.2x	4.7x
Sun, 21 Dec 2025	₹20.5t	₹4.2t	₹614.5b	28.2x	33.3x	4.8x
Tue, 18 Nov 2025	₹20.6t	₹4.2t	₹611.4b	30.1x	33.7x	4.9x
Thu, 16 Oct 2025	₹20.1t	₹4.1t	₹589.5b	30x	34.1x	4.9x
Sat, 13 Sep 2025	₹20.6t	₹4.1t	₹589.1b	31.5x	35x	5.1x
Mon, 11 Aug 2025	₹19.8t	₹4.1t	₹592.7b	32.4x	33.4x	4.9x
Wed, 09 Jul 2025	₹20.4t	₹4.0t	₹594.1b	33.4x	34.3x	5.1x
Fri, 06 Jun 2025	₹20.1t	₹4.0t	₹595.3b	32.5x	33.8x	5.1x
Sun, 04 May 2025	₹19.6t	₹3.9t	₹563.0b	29.4x	34.8x	5x
Tue, 01 Apr 2025	₹19.4t	₹3.9t	₹559.4b	29.7x	34.7x	5x
Thu, 27 Feb 2025	₹18.5t	₹3.9t	₹561.5b	27.3x	32.9x	4.7x
Sat, 25 Jan 2025	₹19.9t	₹3.8t	₹527.3b	31.6x	37.8x	5.2x
Mon, 23 Dec 2024	₹20.7t	₹3.8t	₹526.7b	33.6x	39.3x	5.4x
Wed, 20 Nov 2024	₹20.1t	₹3.8t	₹526.2b	31.7x	38.3x	5.3x
Fri, 18 Oct 2024	₹21.4t	₹3.7t	₹492.6b	40.8x	43.5x	5.7x
Sun, 15 Sep 2024	₹21.7t	₹3.7t	₹492.6b	42.8x	44.1x	5.8x
Tue, 13 Aug 2024	₹20.4t	₹3.8t	₹486.1b	36.5x	41.9x	5.4x
Thu, 11 Jul 2024	₹18.7t	₹3.6t	₹449.9b	34.8x	41.5x	5.2x
Sat, 08 Jun 2024	₹17.4t	₹3.6t	₹450.7b	32.7x	38.6x	4.9x
Mon, 06 May 2024	₹17.1t	₹3.5t	₹418.8b	34.1x	40.9x	4.9x
Wed, 03 Apr 2024	₹17.2t	₹3.5t	₹418.9b	33.1x	41.1x	5x
Fri, 01 Mar 2024	₹17.0t	₹3.5t	₹418.7b	33.2x	40.6x	4.9x
Sun, 28 Jan 2024	₹15.8t	₹3.4t	₹396.1b	34.6x	39.8x	4.7x
Tue, 26 Dec 2023	₹14.6t	₹3.4t	₹395.2b	32.2x	37x	4.3x
Thu, 23 Nov 2023	₹14.1t	₹3.4t	₹395.1b	30.8x	35.8x	4.2x
Sat, 21 Oct 2023	₹13.1t	₹3.3t	₹369.8b	30x	35.4x	4x
Mon, 18 Sep 2023	₹13.3t	₹3.3t	₹369.5b	29.5x	36.1x	4.1x
Wed, 16 Aug 2023	₹13.0t	₹3.3t	₹366.6b	29.4x	35.5x	4x

Current Industry PE

Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 36.6x.

The industry is trading close to its 3-year average PS ratio of 4.9x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 21% per year over the last three years.
Revenues for these companies have grown 12% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?


IN Market	1.27%
Healthcare	0.61%
Pharma	0.43%
Pharma	0.43%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
524558 Neuland Laboratories	₹22.84k	19.8% +₹48.4b	74.2%	PE58.9x
AUROPHARMA Aurobindo Pharma	₹1.66k	4.9% +₹44.8b	59.1%	PE25.7x
530549 Shilpa Medicare	₹759.60	24.2% +₹29.0b	82.6%	PE50x
ALIVUS Alivus Life Sciences	₹1.33k	14.6% +₹20.8b	42.3%	PE27.1x
500124 Dr. Reddy's Laboratories	₹1.17k	2.1% +₹20.3b	-3.3%	PE29.5x

Piramal Pharma Limited Expands Peptide API Facility with Advanced Spray Drying Suite

Piramal Pharma Solutions has launched a state-of-the-art spray drying suite at its dedicated peptide development and manufacturing facility in Turbhe, India. This strategic expansion enables PPS to address the complex formulation challenges associated with peptides and other complex molecules and support the growing demand for these innovative molecules. Spray drying transforms liquid formulations into dry powders in a single step, enabling drug developers to enhance bioavailability, achieve precise particle size, and process sensitive compounds safely. This technique is especially critical for peptides, which are unstable at high temperatures and often require strict control over particle properties. Its gentle and efficient nature enables drug developers to improve solubility, streamline scale-up, and increase speed, all while preserving the molecular integrity of their peptide API. The new spray drying suite operates as a closed-loop system, equipped with its own inert gas supply and advanced safety measures, including specialized HVAC, airlocked entries and exits, operator isolation, and a dedicated cleaning area. This enables the safe handling of potent compounds and organic solvents requiring up to Band 5 containment. To further strengthen these capabilities, the processing area maintains ISO Class 8 (Class 100,000) cleanliness standards, ensuring strict control of the environment throughout operations. Engineered for small-volume, high potency batches, the unit supports a feed rate of up to 1 liter per hour. It can spray dry highly concentrated solutions -- even those with up to 30% water content -- making it particularly valuable for the formulation of biomolecules and large peptides. Under optimal conditions, the suite can also be leveraged for low-volume small-molecule formulations.

Indian (NIFTY) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Dividend of ₹5.00 announced

Results: Aurobindo Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2027 earnings released: EPS: ₹57.92 (vs ₹39.87 in 1Q 2026)

Dividend of ₹0.60 announced

500124: Fair Outlook Will Balance New Drug Launches And Compliance Developments

524558: Capacity Plans And Transdermal CDMO Work Will Shape Balanced Future Outlook

Piramal Pharma Limited Expands Peptide API Facility with Advanced Spray Drying Suite

ACUTAAS: Higher Profitability Outlook And Q1 Results Will Support A Measured Future

Results: Sun Pharmaceutical Industries Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2027 earnings: EPS in line with analyst expectations despite revenue beat

Upcoming dividend of ₹20.00 per share

Price target increased by 8.3% to ₹5,322

Lupin Limited Launches Generic Sugammadex Injection In The U.S. After Receiving U.S. FDA Approval

Full year 2026 earnings: EPS misses analyst expectations

Cipla Limited Receives U.S. Fda Approval for Generic Advair Diskus

Zydus Lifesciences Limited Announces Temporary Suspension of Operations Due to Torrential Rain